http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011037857-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b65747ed78f05dd9ebe107b50ce2855 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2010-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28645ea80a4655523e294fc0a901d79a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2291e91ce6dba727215b25cc88af8526 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_004d5f8c8c3658218fc90380e4ffd76a |
| publicationDate | 2011-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2011037857-A |
| titleOfInvention | 6- (3-Chloro-2-fluorobenzyl) -1-[(2S) -1-hydroxy-3-methylbutan-2-yl] -7-methoxy-4-oxo for the treatment of retroviral infections Use of -1,4-dihydroquinoline-3-carboxylic acid or a salt thereof |
| abstract | [PROBLEMS] To provide a therapeutic agent for retroviral infection, a therapeutic composition and a kit. A therapeutically effective amount of 6- (3-chloro-2-fluorobenzyl) -1-[(2S) -1-hydroxy-3-methylbutan-2-yl] -7-methoxy-4-oxo-1 , 4-Dihydroquinoline-3-carboxylic acid (hereinafter referred to as Compound I) or a pharmaceutically acceptable salt thereof. Furthermore, use of compound I or a salt thereof for an inhibitor of integrase activity. Compound I or salts thereof are also effective in inhibiting the replication of retroviruses that are resistant to at least one antiretroviral agent. Compound I or a salt thereof is administered alone or in combination with at least one antiretroviral agent other than Compound I or a salt thereof. Furthermore, manufacture of a kit containing Compound I or a salt thereof. [Selection figure] None |
| priorityDate | 2006-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 479.